Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926702 · ClinicalTrials.gov registry record · Early Phase 1
Tau Imaging With JNJ067
A Early Phase 1 study, sponsored by University of California, Berkeley.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03926702 is a Early Phase 1 study that has completed, run by University of California, Berkeley. The registered enrollment target is 18 participants.
The verdict
NCT03926702, a Early Phase 1 study, has completed, sponsored by University of California, Berkeley.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This protocol is designed to assess the utility of a new positron emission tomography (PET) radiopharmaceutical to image tau, \[18F\] JNJ067, invented by Janssen Pharmaceutical companies of Johnson \& Johnson. To date, the radiopharmaceutical has been used in a small group of patients and controls (\<20). The study plans to expand the range and number of subjects, to examine a total of 18 participants including controls and patients with Alzheimer's disease (AD) and other dementias. All patients will be recruited from the University of California, San Francisco (UCSF) Memory and Aging Center (MAC) and controls will be recruited from the University of California, Berkeley Aging Cohort Study (BACS). Patients will undergo a multidisciplinary clinical evaluation for diagnosis and a cognitive assessment at the MAC; controls will undergo the usual BACS cognitive assessment performed on the Berkeley campus. Following these evaluations UCSF subjects will undergo magnetic resonance imaging (MRI) scanning at the UCSF Neuroimaging Center and blood sampling for genetic testing also at UCSF, and BACS subjects will undergo an MRI at the University of California Berkeley 3T Brain Imaging Center (in Li Ka Shing hall on the Berkeley campus) and blood sampling for genetic testing at the time of the PET scan. All subjects will come to Lawrence Berkeley National Law (LBNL) where they will have, on the same day, a C-11 Pittsburgh compound B (PIB) PET scan to measure brain amyloid, and an F-18 JNJ067 PET scan to measure brain tau. These scans will be examined and analyzed by LBNL staff, and data will be processed to examine basic questions about the quantitative behavior of JNJ067. Scan results will not be returned to control subjects, but physicians at UCSF will receive scan results on MAC patients and will share results with participants. As part of this protocol, the investigators also plan to share the acquired data widely. All data will be de-identified. Data will be shared with t
Interventions
- DRUG Radiopharmaceuticals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-06-18 |
| Est. Completion | 2021-01-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926702
The ClinicalTrials.gov registry entry for NCT03926702 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Berkeley, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiopharmaceuticals is the first listed.
NCT03926702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926702 about?
NCT03926702 is a clinical study titled "Tau Imaging With JNJ067". This protocol is designed to assess the utility of a new positron emission tomography (PET) radiopharmaceutical to image tau, \[18F\] JNJ067, invented by Janssen Pharmaceutical companies of Johnson \& Johnson. To date, the radiopharmaceutical has been used in a small group of patients and controls (...
What is the current status of trial NCT03926702?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2019-06-18. Estimated completion is 2021-01-06.
What interventions are being tested in trial NCT03926702?
The interventions under investigation include: Radiopharmaceuticals (DRUG).
Who is sponsoring clinical trial NCT03926702?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.